One week after the initial ophthalmological examination and ravulizumab administration, the patient’s BP decreased to 164/92 mmHg, while severe hemolytic anemia (Hb 8.8 mg/dL) and acute renal failure (urea 197 mg/dL and creatinine 8.67 mg/dL) persisted. The gene discussed is GSTM1; the disease is acute kidney injury.